Amgen (NASDAQ:AMGN) announced today that its Board of Directors has
appointed François de Carbonnel to the
Company's Board. Mr. de Carbonnel, 61, is a consultant and corporate
financial advisor. He is also chairman of the board of Thomson S.A.
(Euronext Paris:18453; NYSE:TMS), an international multimedia
corporation. He is also a member of the boards of Pages Jaunes S.A., a
French public company, Quilvest S.A., a public Luxembourg company,
Ecofin Global Utilities Hedge Fund Ltd. and Ecofin North America
Utilities Hedge Fund Ltd., both Irish public companies. His appointment
brings the number of Amgen Board members to 12. Mr. de Carbonnel will
serve as a member of the Audit and Governance and Nominating Committees
of the Board.
Until the end of 2006, Mr. de Carbonnel was a consultant/senior advisor
to Citigroup’s Corporate and Investment Bank
and to Citigroup Venture Capital, based in London. Previously, he was a
managing director and member of the Operating Committee (New York and
London) of Citigroup’s Corporate and
Investment Bank, which he joined in 1999. He held different senior
positions globally and in Europe. Prior to Citigroup he was chairman and
chief executive officer of MIDIAL S.A. based in Paris.
About Amgen
Amgen discovers, develops, manufactures and delivers innovative human
therapeutics. A biotechnology pioneer since 1980, Amgen was one of the
first companies to realize the new science’s
promise by bringing safe and effective medicines from lab, to
manufacturing plant, to patient. Amgen therapeutics have changed the
practice of medicine, helping millions of people around the world in the
fight against cancer, kidney disease, rheumatoid arthritis, and other
serious illnesses. With a deep and broad pipeline of potential new
medicines, Amgen remains committed to advancing science to dramatically
improve people’s lives. To learn more about
our pioneering science and our vital medicines, visit www.amgen.com.
Amgen, Thousand Oaks
David Polk, 805-447-4613 (media)
Arvind
Sood, 805-447-1060 (investors)
